Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug ALC-2203 aims to soothe bronchitis cough

NCT ID NCT07061925

Symptom relief Sponsor: Korea Arlico Pharm. Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested whether the experimental drug ALC-2203 can reduce symptoms of acute bronchitis, like cough and chest pain. 169 adults with moderate to severe symptoms took either ALC-2203, an active comparator, or a placebo for 7 days. Researchers measured changes in a symptom score to see if the drug works better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ALC-2203
What this could lead to
If successful, this could lead to a new treatment option to reduce cough and other bronchitis symptoms faster.
What could go wrong
This is an early Phase 2 dose-finding trial with only 169 participants, so results may not confirm effectiveness or safety for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

169 people

The number who actually took part.

Started

Apr 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female participants aged 19 years or older. 2. Patients diagnosed with acute bronchitis with: * A Bronchitis Severity Score (BSS) of ≥ 5 at Visit 2. * A sputum subscore of at least 1 at Visit 2. 3. Onset of acute bronchitis symptoms within 48 hours prior to Visit 2. 4. Patients who voluntarily agree to participate Exclusion Criteria: 1. Patients who, in the opinion of the investigator, have severe respiratory diseases such as allergic asthma, chronic bronchitis, or asthma 2. Patients who are currently taking, or are expected to take during the study period, antitussive or expectorant medications containing agents such as codeine or dextromethorphan 3. Patients who have participated in another clinical trial within 4 weeks prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute bronchitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute bronchitis

Contacts and locations

Locations

  • Konkuk University Medical Center

    Seoul, 05030, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.